A Phase 1/2 interventional study of Docetaxel and Pertuzumab in Breast Cancer, sponsored by Hoffmann-La Roche. Completed at 8 sites in 4 countries. Open to participants aged 18 Years and older. Per ClinicalTrials.gov, last updated 2017-04-06.
Sponsored by Hoffmann-La Roche · Phase 1/2, Interventional, and Treatment
Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →
Among 264 studies testing docetaxel in Breast Neoplasms — 19 open to participants now, 26 under way, 8 of them phase 3. Docetaxel · Breast Neoplasms.
Among the 264 studies testing docetaxel in Breast Neoplasms, this one is the 92nd largest by enrollment of the 248 interventional ones that give a count, is one of 13 that started in 2009, is one of 17 in phase 1/2, and was the 175th registered.
14,837 studies on the registry are indexed under Breast Neoplasms; 3,320 are open to participants now.
Browse Breast Neoplasms studies →19 of the 264 studies testing docetaxel in Breast Neoplasms are open now, in 9 countries. Recruiting first, the newest first:
The First Affiliated Hospital with Nanjing Medical University · Sites in China
Ages 18–75 · Women only
Rutgers, The State University of New Jersey · Sites in United States
Ages 18–90
Shanghai JMT-Bio Inc. · Sites in China
Ages 18+
Jazz Pharmaceuticals · Sites in United States, Germany, Italy and 1 more country
Ages 18+
University of Chicago · Sites in Nigeria
Ages 18+ · Women only
By country, each count listing its studies:
Docetaxel: first FDA approval 1996 (TAXOTERE), first EMA approval 1995. What it is approved for, and how studies give it, is on its page →
Of the 2,399 Breast Neoplasms studies recruiting now, 1,570 (65%) set no upper age limit and 592 (25%) stop at 75 or younger; 103 take children under 18; 215 take healthy volunteers.
This study: 18 Years and older · all sexes · no healthy volunteers.
The full table on the hub →This tab as a report to print or save as PDF → With an account.
264 studies; the count open now beside each. This study's row is marked.
A study in two phases is counted once above. Listed by phase, each with its combined phases: Phase 1 40 · Phase 2 178 · Phase 3 55 · Phase 4 5
First in 1993; this study’s year is marked. 13 started in 2009.
By drug class, each counting the studies that test any of its medicines:
This study's enrollment of 98 is above the median of 72 across 10,903 interventional studies indexed under Breast Neoplasms.
Median enrollment 68 across the 248 interventional studies. Of the 207 that completed or were terminated, 58 (28%) have results posted.
This tab as a report to print or save as PDF → With an account.
58 of 264 have an industry lead sponsor. The 10 most frequent:
Hoffmann-La Roche is the lead sponsor of 2,102 studies on the registry; 89 are open to participants now.
Of its 330 completed or terminated interventional studies of FDA-regulated products, 248 (75%) have results posted.
229 studies in Breast Neoplasms by Hoffmann-La Roche: 16 open now, 28 under way, 13 of them phase 3. Of 193 finished, 120 (62%) have results posted.
Among the 229 studies in Breast Neoplasms by Hoffmann-La Roche, this one is the 105th largest by enrollment of the 170 interventional ones that give a count, is one of 18 that started in 2009, is one of 11 in phase 1/2, and was the 55th registered.
Hoffmann-La Roche’s Breast Neoplasms studies by the year they started, since 1998.
3 of the studies testing docetaxel in Breast Neoplasms that are under way reach primary completion within a year, 1 of them phase 3. Phase 3 first, then by date:
| Study | Primary completion |
|---|---|
| NCT06747338Phase 3Shanghai JMT-Bio Inc.A Phase III Study of KN026 in Combination With HB1801 ± Carboplatin as Neoadjuvant Treatment for Early or Locally Advanced HER2-Positive Breast Cancer | 2026-12-16 |
| NCT05645380University of Kansas Medical CenterNeoadjuvant TIL- and Response-Adapted Chemoimmunotherapy for TNBC | 2026-12 |
| NCT06409390H. Lee Moffitt Cancer Center and Research InstituteSequential Therapies Modeled on Evolutionary Dynamics for Breast Cancer | 2027-04 |
Add all 3 to your calendar (.ics) → With an account.
Among the 264 studies testing docetaxel in Breast Neoplasms, from their registry updates:
Among Hoffmann-La Roche’s 229 in Breast Neoplasms:
This tab as a report to print or save as PDF → With an account.
This is an open-label, multi-center, non-randomized study of the safety and tolerability of the combination of T-DM1 plus docetaxel for the treatment of participants with metastatic breast cancer (MBC) and of T-DM1 plus docetaxel with or without pertuzumab, for the treatment of participants with locally advanced breast cancer (LABC). The study comprises an initial dose finding (feasibility) part to determine the maximum tolerated dose (MTD) of T-DM1 and docetaxel, followed by an extension part aiming to consolidate the safety and efficacy of the recommended docetaxel/T-DM1 combination regimen.
Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.
For MBC participants:
For LABC participants:
Exclusion Criteria:
For MBC participants:
For LABC participants:
Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
A scale of how much an illness limits everyday activity. For people being assessed to join a study, scores run from 0 (fully active) to 4; lower is more active.
Studies most often ask for 0–1 or 0–2. Your doctor gives the score; the WHO scale uses the same steps. The full scale also has 5, which records death.
HER2 is a protein, made from the ERBB2 gene, that drives the growth of some cancers. A study may look for a level of the protein, extra copies of the gene, or a particular change in it.
In breast cancer, protein tests are read as HER2-positive, HER2-low or HER2-negative; other cancers use their own rules. Check which test result the study requires.
Cancer that has spread from where it began to other parts of the body. “Metastatic” cancer is cancer that has spread this way.
Cancer deposits in the brain from a cancer that started elsewhere in the body (CNS metastases include the spinal cord).
Studies differ: some leave out any brain metastases, some accept ones treated and stable for some weeks. Check what this study allows.
ECOG performance status
A scale of how much an illness limits everyday activity. For people being assessed to join a study, scores run from 0 (fully active) to 4; lower is more active.
Studies most often ask for 0–1 or 0–2. Your doctor gives the score; the WHO scale uses the same steps. The full scale also has 5, which records death.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
HER2
HER2 is a protein, made from the ERBB2 gene, that drives the growth of some cancers. A study may look for a level of the protein, extra copies of the gene, or a particular change in it.
In breast cancer, protein tests are read as HER2-positive, HER2-low or HER2-negative; other cancers use their own rules. Check which test result the study requires.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Metastases
Cancer that has spread from where it began to other parts of the body. “Metastatic” cancer is cancer that has spread this way.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Brain metastases
Cancer deposits in the brain from a cancer that started elsewhere in the body (CNS metastases include the spinal cord).
Studies differ: some leave out any brain metastases, some accept ones treated and stable for some weeks. Check what this study allows.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Participants with human epidermal growth factor receptor 2 (HER2)-positive MBC will receive docetaxel (Doc) 75 milligrams per square meter (mg/m\^2) intravenous (IV) infusion on Day 1 and T-DM1 2.4 milligrams per kilogram (mg/kg) IV infusion on Day 2 of Cycle 1 followed by T-DM1 75 mg/m\^2 and docetaxel 2.4 mg/kg IV infusion on Day 1 of each 3-week cycle for a minimum of 6 cycles. After 6 cycles, docetaxel 75 mg/m\^2 will be stopped and T-DM1 2.4 mg/kg will be continued until confirmed evidence of disease progression, unacceptable toxicity, or withdrawal of participant consent.
Drug: Docetaxel · Drug: Trastuzumab emtansine
Participants with HER2-positive MBC will receive docetaxel 60 mg/m\^2 IV infusion on Day 1 and T-DM1 2.4 mg/kg IV infusion on Day 2 of Cycle 1 followed by T-DM1 60 mg/m\^2 and docetaxel 2.4 mg/kg IV infusion on Day 1 of each 3-week cycle for a minimum of 6 cycles. After 6 cycles, docetaxel 60 mg/m\^2 will be stopped and T-DM1 2.4 mg/kg will be continued until confirmed evidence of disease progression, unacceptable toxicity, or withdrawal of participant consent.
Drug: Docetaxel · Drug: Trastuzumab emtansine
Participants with HER2-positive MBC will receive docetaxel 60 mg/m\^2 IV infusion and T-DM1 2.4 mg/kg IV infusion on Day 1 of each 3-week cycle for a minimum of 6 cycles. After 6 cycles, docetaxel 60 mg/m\^2 will be stopped and T-DM1 2.4 mg/kg will be continued until confirmed evidence of disease progression, unacceptable toxicity, or withdrawal of participant consent.
Drug: Docetaxel · Drug: Trastuzumab emtansine
Participants with HER2-positive MBC will receive docetaxel 60 mg/m\^2 IV infusion and T-DM1 3.6 mg/kg IV infusion on Day 1 of each 3-week cycle for a minimum of 6 cycles. After 6 cycles, docetaxel 60 mg/m\^2 will be stopped and T-DM1 3.6 mg/kg will be continued until confirmed evidence of disease progression, unacceptable toxicity, or withdrawal of participant consent.
Drug: Docetaxel · Drug: Trastuzumab emtansine
Participants with HER2-positive LABC will receive T-DM1 3.6 mg/kg IV infusion and docetaxel 60/75/100 mg/m\^2 IV infusion on Day 1 of each 3-week cycle, for 6 cycles. Study treatment will be administered for up to 6 cycles or until unacceptable toxicity, and prior to surgery.
Drug: Docetaxel · Drug: Trastuzumab emtansine
Participants with HER2-positive LABC will receive T-DM1 3.6 mg/kg Iv infusion, docetaxel 60/75 mg/m\^2 IV infusion, and pertuzumab 840 mg (for Cycle 1) or 420 mg (for remaining cycles) IV infusion on Day 1 of each 3-week cycle, for 6 cycles. Study treatment will be administered for up to 6 cycles or until unacceptable toxicity, and prior to surgery.
Drug: Docetaxel · Drug: Pertuzumab · Drug: Trastuzumab emtansine
Docetaxel will be administered on Day 1 of each 3-week cycle at a dose specified in the respective arms (as per summary of product characteristics \[SmPC\]).
Pertuzumab at a loading dose of 840 mg IV infusion on Day 1 of Cycle 1 followed by maintenance dose of 420 mg IV infusion on Day 1 of each 3-week cycle.
T-DM1 will be administered on Day 1 or Day 2 of each 3-week cycle at a dose specified in the respective arms.
Also known as: T-DM1
Number of Participants With Dose Limiting Toxicity (DLT) - MBC and LABC Feasibility Population
DLTs included (as per National Cancer Institute Common Terminology Criteria for Adverse Events \[NCI CTCAE\] grading): Grade 4 thrombocytopenia, thrombocytopenia of any grade with concurrent hemorrhage or requiring blood platelet transfusion, or thrombocytopenia not recovered by Day 21 to at least 100,000/microliter (mcL); Grade 4 neutropenia lasting for more than 7 days; Febrile neutropenia; Grade greater than or equal to (\>/=) 3 neurotoxicity in the form of peripheral neuropathy or peripheral neurotoxicity not improving to baseline or Grade less than or equal to (\</=) 1 by Day 21; Any non-hematological toxicity of Grade \>/= 3 except for alopecia, fever, and chills, not improving to baseline or Grade \</=1 by Day 21, despite adequate toxicity management; Any subjective intolerable toxicity felt by the investigator to be related to either study treatment; Any other treatment-related toxicity prohibiting the start of the Cycle 2 on Day 22; Fulminant skin rash.
Time frame: Cycle 1 (up to 21 days)
Percentage of Participants With Adverse Events (AEs) or Serious AEs (SAEs) - MBC and LABC Population
An AE is any new untoward medical occurrence or worsening of a pre-existing medical condition which does not necessarily have a causal relationship with this treatment. SAE is any untoward medical occurrence that at any dose results in death, is life-threatening, requires in-patient hospitalization or causes prolongation of existing hospitalization, results in persistent or significant disability/incapacity, is a congenital anomaly/birth defect, results in development of drug dependency or drug abuse, is an important medical event.
Time frame: Baseline up to 28 days after last dose for MBC participants and for LABC participants who could not undergo surgery, and up to 6 weeks post-surgery for LABC participants who underwent surgery (maximum up to approximately 3 years)
Percentage of Participants With Progression-Free Survival (PFS) Event - MBC Population
PFS was defined as the time interval between the date of the start of treatment and the date of first documentation of progressive disease (PD) or death from any cause, whichever occurred first. Response was based on Response Evaluation Criteria in Solid Tumors (RECIST) Version 1.0 (v1.0). For target lesions (TLs), PD was at least a 20 percent (%) increase in the sum of longest diameter (LD) of target lesions, taking as reference the smallest sum LD recorded since the treatment started or the appearance of one or more lesions. For non-target lesions (NTLs), PD was the appearance of one or more new lesions and/or unequivocal progression of existing NTLs. Data for participants without PD or death was censored at the time of the last response assessment. Percentage of participants with PFS event was calculated as the (number of participants with PFS event \[PD or death\]) divided by (total number of participants), and then multiplied by 100.
Time frame: Baseline until disease progression or death (up to approximately 3 years)
PFS - MBC Population
PFS was defined as the time interval between the date of the start of treatment and the date of first documentation of PD or death from any cause, whichever occurred first. Response was based on RECIST v1.0. For TLs, PD was at least a 20 % increase in the sum of LD of TLs, taking as reference the smallest sum LD recorded since the treatment started or the appearance of one or more lesions. For NTLs, PD was the appearance of one or more new lesions and/or unequivocal progression of existing NTLs. Median PFS time was calculated using Kaplan-Meier estimates. Data for participants without PD or death was censored at the time of the last response assessment.
Time frame: Baseline until disease progression or death (up to approximately 3 years)
Percentage of Participants With a Best Overall Response (BOR) of Complete Response (CR) or Partial Response (PR) - MBC Population
BOR was defined as CR or PR recorded from baseline until disease progression/recurrence according to RECIST v1.0 criteria. For TLs, CR was defined as the disappearance of all TLs, and PR was defined as at least a 30% decrease in the sum of LDs of the TLs, taking as a reference the baseline (BL) sum of LDs. For NTLs, CR was defined as the disappearance of all NTLs and normalization of tumor marker levels. Percentage of participants with BOR rate was calculated as the (number of participants with CR or PR) divided by (total number of participants), and then multiplied by 100. The 95% confidence interval (Cl) was determined using the Pearson-Clopper method.
Time frame: Baseline until disease progression or recurrence (up to approximately 3 years)
Percentage of Participants With Treatment Failure - MBC Population
Treatment failure was defined as the discontinuation of treatment for any reason, including the following qualifying events: PD, death from any cause, withdrawal from study treatment, or initiation of nonprotocol anti-cancer therapy. Percentage of participants with treatment failure was calculated as the (number of participants with treatment failure) divided by (total number of participants), and then multiplied by 100.
Time frame: Baseline until end of treatment (up to 39.8 months)
Time to Treatment Failure (TTF) - MBC Population
TTF was defined as the time interval between the date of start of treatment and the date of PD, death from any cause, withdrawal from study treatment, or initiation of non-protocol anti-cancer therapy, whichever occurred first. Participants without an event at the time of the analysis were censored at the date of the last follow-up assessment. Median TTF was estimated using the Kaplan-Meier method.
Time frame: Baseline until end of treatment (up to 39.8 months)
Percentage of Participants With CR or PR or Stable Disease (SD) for at Least 6 Months [Clinical Benefit Rate (CBR)] - MBC Population
CBR was defined as percentage of participants experiencing SD of at least 6 months from the start of treatment plus CR or PR according to the RECIST v1.0 criteria. For TLs: CR- disappearance of all TLs. PR- at least 30% decrease in the sum of LDs of the TLs, taking as a reference the BL sum of LDs. PD- at least 20% increase in the sum of LD of TLs, taking as reference the smallest sum LD recorded since the treatment started or the appearance of one or more lesions. SD- neither sufficient shrinkage to qualify for PR nor sufficient increase to qualify for PD. For NTLs: CR- disappearance of all NTLs and normalization of tumor marker levels. SD- persistence of one or more NTLs and/or maintenance of tumor marker level above the normal limits. Percentage of participants= number of participants with CR/PR/SD divided by total number of participants, and then multiplied by 100. 95% CI was determined using the Pearson-Clopper method.
Time frame: Baseline until disease progression, recurrence or death (up to approximately 3 years)
Duration of Response - MBC Population
Duration of response was calculated for participants with CR or PR based on the RECIST v1.0 criteria. Duration of response was defined as the time interval between the date the CR or PR was first recorded and the date on which PD was first noted or date of death, whichever occurred first. Participants with no documented PD after CR or PR were censored at the last date at which they were known to have had the CR or PR, respectively. Median duration of response was estimated using the Kaplan-Meier method.
Time frame: Baseline until disease progression, recurrence or death (up to approximately 3 years)
Percentage of Participants With Pathological CR (pCR) - LABC Population
The pCR was defined as the absence of invasive neoplastic cells at microscopic examination of the tumor remnants and lymph nodes after surgery following primary systemic therapy.
Time frame: Within 6 weeks of post-surgery (up to approximately 3 years)
Percentage of Participants With a BOR of CR or PR - LABC Population
BOR was defined as CR or PR recorded from baseline until disease progression/recurrence according to RECIST v1.0 criteria. For TLs, CR was defined as the disappearance of all TLs, and PR was defined as at least a 30% decrease in the sum of LDs of the TLs, taking as a reference the baseline (BL) sum of LDs. For NTLs, CR was defined as the disappearance of all NTLs and normalization of tumor marker levels. Percentage of participants with BOR rate was calculated as the (number of participants with CR or PR) divided by (total number of participants), and then multiplied by 100. The 95% Cl was determined using the Pearson-Clopper method.
Time frame: Baseline until disease progression, recurrence or death (up to approximately 3 years)
Number of Participants With Anti-Therapeutic Antibody (ATA) Response to Trastuzumab - MBC and LABC Population
Number of participants with ATA response was reported. Data for this outcome measure was planned to be reported for overall MBC and LABC participants and not by individual treatment arms.
Time frame: Baseline (Day 1 of Cycle 1), Post baseline (at first follow-up visit [28 days after last dose of study drug][up to approximately 145 weeks])
Maximum Observed Concentration (Cmax) of Serum Trastuzumab Emtansine
Time frame: Cycle 1: pre-dose (Hour [Hr] 0), 0.25, 4 hrs post end of infusion (EOI) of T-DM1 on Day 2; on Days 3 and 8. Cycle 2: pre-dose (Hr 0), 0.25, 4 hrs post EOI of T-DM1 on Day 1; on Day 8 (1 cycle = 21 days) (T-DM1 infusion duration = 1.5 hrs)
Apparent Terminal Half-Life (t1/2) of Serum Trastuzumab Emtansine
Time frame: Cycle 1: pre-dose (Hr 0), 0.25, 4 hrs post EOI of T-DM1 on Day 2; on Days 3 and 8. Cycle 2: pre-dose (Hr 0), 0.25, 4 hrs post EOI of T-DM1 on Day 1; on Day 8 (1 cycle = 21 days) (T-DM1 infusion duration = 1.5 hrs)
Area Under the Concentration-Time Curve From Time 0 to Infinity (AUCinf) of Serum Trastuzumab Emtansine
Time frame: Cycle 1: pre-dose (Hr 0), 0.25, 4 hrs post EOI of T-DM1 on Day 2; on Days 3 and 8. Cycle 2: pre-dose (Hr 0), 0.25, 4 hrs post EOI of T-DM1 on Day 1; on Day 8 (1 cycle = 21 days) (T-DM1 infusion duration = 1.5 hrs)
Clearance (CL) of Serum Trastuzumab Emtansine
Time frame: Cycle 1: pre-dose (Hr 0), 0.25, 4 hrs post EOI of T-DM1 on Day 2; on Days 3 and 8. Cycle 2: pre-dose (Hr 0), 0.25, 4 hrs post EOI of T-DM1 on Day 1; on Day 8 (1 cycle = 21 days) (T-DM1 infusion duration = 1.5 hrs)
Volume of Distribution at Steady State (Vss) of Serum Trastuzumab Emtansine
Time frame: Cycle 1: pre-dose (Hr 0), 0.25, 4 hrs post EOI of T-DM1 on Day 2; on Days 3 and 8. Cycle 2: pre-dose (Hr 0), 0.25, 4 hrs post EOI of T-DM1 on Day 1; on Day 8 (1 cycle = 21 days) (T-DM1 infusion duration = 1.5 hrs)
Cmax of Total Serum Trastuzumab
Time frame: Cycle 1: pre-dose (Hr 0), 0.25, 4 hrs post EOI of T-DM1 on Day 2; on Days 3 and 8. Cycle 2: pre-dose (Hr 0), 0.25, 4 hrs post EOI of T-DM1 on Day 1; on Day 8 (1 cycle = 21 days) (T-DM1 infusion duration = 1.5 hrs)
t1/2 of Total Serum Trastuzumab
Time frame: Cycle 1: pre-dose (Hr 0), 0.25, 4 hrs post EOI of T-DM1 on Day 2; on Days 3 and 8. Cycle 2: pre-dose (Hr 0), 0.25, 4 hrs post EOI of T-DM1 on Day 1; on Day 8 (1 cycle = 21 days) (T-DM1 infusion duration = 1.5 hrs)
AUCinf of Total Serum Trastuzumab
Time frame: Cycle 1: pre-dose (Hr 0), 0.25, 4 hrs post EOI of T-DM1 on Day 2; on Days 3 and 8. Cycle 2: pre-dose (Hr 0), 0.25, 4 hrs post EOI of T-DM1 on Day 1; on Day 8 (1 cycle = 21 days) (T-DM1 infusion duration = 1.5 hrs)
CL of Total Serum Trastuzumab
Time frame: Cycle 1: pre-dose (Hr 0), 0.25, 4 hrs post EOI of T-DM1 on Day 2; on Days 3 and 8. Cycle 2: pre-dose (Hr 0), 0.25, 4 hrs post EOI of T-DM1 on Day 1; on Day 8 (1 cycle = 21 days) (T-DM1 infusion duration = 1.5 hrs)
Vss of Total Serum Trastuzumab
Time frame: Cycle 1: pre-dose (Hr 0), 0.25, 4 hrs post EOI of T-DM1 on Day 2; on Days 3 and 8. Cycle 2: pre-dose (Hr 0), 0.25, 4 hrs post EOI of T-DM1 on Day 1; on Day 8 (1 cycle = 21 days) (T-DM1 infusion duration = 1.5 hrs)
Cmax of Plasma N2'-Deacetyl-N2'-(3-mercapto-1-oxopropyl)-Maytansine (DM1)
DM1 is the metabolite of trastuzumab emtansine.
Time frame: Cycle 1: pre-dose (Hr 0), 0.25, 4 hrs post EOI of T-DM1 on Day 2; on Days 3 and 8. Cycle 2: pre-dose (Hr 0), 0.25, 4 hrs post EOI of T-DM1 on Day 1; on Day 8 (1 cycle = 21 days) (T-DM1 infusion duration = 1.5 hrs)
t1/2 of Plasma DM1
Time frame: Cycle 1: pre-dose (Hr 0), 0.25, 4 hrs post EOI of T-DM1 on Day 2; on Days 3 and 8. Cycle 2: pre-dose (Hr 0), 0.25, 4 hrs post EOI of T-DM1 on Day 1; on Day 8 (1 cycle = 21 days) (T-DM1 infusion duration = 1.5 hrs)
AUCinf of Plasma DM1
Time frame: Cycle 1: pre-dose (Hr 0), 0.25, 4 hrs post EOI of T-DM1 on Day 2; on Days 3 and 8. Cycle 2: pre-dose (Hr 0), 0.25, 4 hrs post EOI of T-DM1 on Day 1; on Day 8 (1 cycle = 21 days) (T-DM1 infusion duration = 1.5 hrs)
Cmax of Plasma Docetaxel
Docetaxel infusion duration = 1 hr (as per summary of product characteristics \[SmPC\])
Time frame: Cycle 1: pre-dose (Hr 0), 0.25, 0.5, 1, 2, 4, 8, 23 hrs post EOI of docetaxel on Day 1. Cycle 2: pre-dose (Hr 0), 0.5 hr and 59 min after start of infusion, 0.25, 0.5, 1, 2, 4, 8, 23 hrs post EOI of docetaxel on Day 1 (1 cycle = 21 days)
t1/2 of Plasma Docetaxel
Docetaxel infusion duration = 1 hr (as per SmPC)
Time frame: Cycle 1: pre-dose (Hr 0), 0.25, 0.5, 1, 2, 4, 8, 23 hrs post EOI of docetaxel on Day 1. Cycle 2: pre-dose (Hr 0), 0.5 hr and 59 min after start of infusion, 0.25, 0.5, 1, 2, 4, 8, 23 hrs post EOI of docetaxel on Day 1 (1 cycle = 21 days)
AUCinf of Plasma Docetaxel
Docetaxel infusion duration = 1 hr (as per SmPC)
Time frame: Cycle 1: pre-dose (Hr 0), 0.25, 0.5, 1, 2, 4, 8, 23 hrs post EOI of docetaxel on Day 1. Cycle 2: pre-dose (Hr 0), 0.5 hr and 59 min after start of infusion, 0.25, 0.5, 1, 2, 4, 8, 23 hrs post EOI of docetaxel on Day 1 (1 cycle = 21 days)
CL of Plasma Docetaxel
Docetaxel infusion duration = 1 hr (as per SmPC)
Time frame: Cycle 1: pre-dose (Hr 0), 0.25, 0.5, 1, 2, 4, 8, 23 hrs post EOI of docetaxel on Day 1. Cycle 2: pre-dose (Hr 0), 0.5 hr and 59 min after start of infusion, 0.25, 0.5, 1, 2, 4, 8, 23 hrs post EOI of docetaxel on Day 1 (1 cycle = 21 days)
Vss of Plasma Docetaxel
Docetaxel infusion duration = 1 hr (as per SmPC)
Time frame: Cycle 1: pre-dose (Hr 0), 0.25, 0.5, 1, 2, 4, 8, 23 hrs post EOI of docetaxel on Day 1. Cycle 2: pre-dose (Hr 0), 0.5 hr and 59 min after start of infusion, 0.25, 0.5, 1, 2, 4, 8, 23 hrs post EOI of docetaxel on Day 1 (1 cycle = 21 days)
| Milestone | MBC: T-DM1 2.4 mg/kg + Doc 75 mg/m^2 (Over 2 Days) | MBC: T-DM1 2.4 mg/kg + Doc 60 mg/m^2 (Over 2 Days) | MBC: T-DM1 2.4 mg/kg + Doc 60 mg/m^2 (Same Day) | MBC: T-DM1 3.6 mg/kg + Doc 60 mg/m^2 (Same Day) | LABC: T-DM1 + Doc (Doublet Regimen) | LABC: T-DM1 + Doc + Pertuzumab (Triplet Regimen) |
|---|---|---|---|---|---|---|
| Started | 6 | 6 | 3 | 6 | 12 | 9 |
| Completed | 1 | 1 | 0 | 1 | 12 | 6 |
| Not completed | 5 | 5 | 3 | 5 | 0 | 3 |
| Withdrew: Progressive disease | 4 | 4 | 2 | 3 | 0 | 0 |
| Withdrew: Physician decision | 0 | 0 | 1 | 0 | 0 | 0 |
| Withdrew: Adverse event | 1 | 1 | 0 | 1 | 0 | 2 |
| Withdrew: Withdrawal by subject | 0 | 0 | 0 | 1 | 0 | 1 |
| Milestone | MBC: T-DM1 2.4 mg/kg + Doc 75 mg/m^2 (Over 2 Days) | MBC: T-DM1 2.4 mg/kg + Doc 60 mg/m^2 (Over 2 Days) | MBC: T-DM1 2.4 mg/kg + Doc 60 mg/m^2 (Same Day) | MBC: T-DM1 3.6 mg/kg + Doc 60 mg/m^2 (Same Day) | LABC: T-DM1 + Doc (Doublet Regimen) | LABC: T-DM1 + Doc + Pertuzumab (Triplet Regimen) |
|---|---|---|---|---|---|---|
| Started | 0 | 0 | 0 | 4 | 28 | 24 |
| Completed | 0 | 0 | 0 | 2 | 24 | 19 |
| Not completed | 0 | 0 | 0 | 2 | 4 | 5 |
| Withdrew: Adverse event | 0 | 0 | 0 | 1 | 4 | 4 |
| Withdrew: Progressive disease | 0 | 0 | 0 | 1 | 0 | 0 |
| Withdrew: Non-compliance with drug | 0 | 0 | 0 | 0 | 0 | 1 |
DLTs included (as per National Cancer Institute Common Terminology Criteria for Adverse Events \[NCI CTCAE\] grading): Grade 4 thrombocytopenia, thrombocytopenia of any grade with concurrent hemorrhage or requiring blood platelet transfusion, or thrombocytopenia not recovered by Day 21 to at least 100,000/microliter (mcL); Grade 4 neutropenia lasting for more than 7 days; Febrile neutropenia; Grade greater than or equal to (\>/=) 3 neurotoxicity in the form of peripheral neuropathy or peripheral neurotoxicity not improving to baseline or Grade less than or equal to (\</=) 1 by Day 21; Any non-hematological toxicity of Grade \>/= 3 except for alopecia, fever, and chills, not improving to baseline or Grade \</=1 by Day 21, despite adequate toxicity management; Any subjective intolerable toxicity felt by the investigator to be related to either study treatment; Any other treatment-related toxicity prohibiting the start of the Cycle 2 on Day 22; Fulminant skin rash.
| participants | MBC: T-DM1 2.4 mg/kg + Doc 75 mg/m^2 (Over 2 Days) | MBC: T-DM1 2.4 mg/kg + Doc 60 mg/m^2 (Over 2 Days) | MBC: T-DM1 2.4 mg/kg + Doc 60 mg/m^2 (Same Day) | MBC: T-DM1 3.6 mg/kg + Doc 60 mg/m^2 (Same Day) | LABC: T-DM1 + Doc (Doublet Regimen) | LABC: T-DM1 + Doc + Pertuzumab (Triplet Regimen) |
|---|---|---|---|---|---|---|
| Number of Participants With Dose Limiting Toxicity (DLT) - MBC and LABC Feasibility Population | 2 | 1 | 0 | 1 | 2 | 2 |
An AE is any new untoward medical occurrence or worsening of a pre-existing medical condition which does not necessarily have a causal relationship with this treatment. SAE is any untoward medical occurrence that at any dose results in death, is life-threatening, requires in-patient hospitalization or causes prolongation of existing hospitalization, results in persistent or significant disability/incapacity, is a congenital anomaly/birth defect, results in development of drug dependency or drug abuse, is an important medical event.
| percentage of participants | MBC: T-DM1 2.4 mg/kg + Doc 75 mg/m^2 (Over 2 Days) | MBC: T-DM1 2.4 mg/kg + Doc 60 mg/m^2 (Over 2 Days) | MBC: T-DM1 2.4 mg/kg + Doc 60 mg/m^2 (Same Day) | MBC: T-DM1 3.6 mg/kg + Doc 60 mg/m^2 (Same Day) | LABC: T-DM1 + Doc (Doublet Regimen) | LABC: T-DM1 + Doc + Pertuzumab (Triplet Regimen) |
|---|---|---|---|---|---|---|
| AEs | 100 | 100 | 100 | 100 | 100 | 100 |
| SAEs | 33.3 | 33.3 | 66.7 | 40.0 | 22.5 | 27.3 |
PFS was defined as the time interval between the date of the start of treatment and the date of first documentation of progressive disease (PD) or death from any cause, whichever occurred first. Response was based on Response Evaluation Criteria in Solid Tumors (RECIST) Version 1.0 (v1.0). For target lesions (TLs), PD was at least a 20 percent (%) increase in the sum of longest diameter (LD) of target lesions, taking as reference the smallest sum LD recorded since the treatment started or the appearance of one or more lesions. For non-target lesions (NTLs), PD was the appearance of one or more new lesions and/or unequivocal progression of existing NTLs. Data for participants without PD or death was censored at the time of the last response assessment. Percentage of participants with PFS event was calculated as the (number of participants with PFS event \[PD or death\]) divided by (total number of participants), and then multiplied by 100.
| percentage of participants | Overall MBC Participants |
|---|---|
| Percentage of Participants With Progression-Free Survival (PFS) Event - MBC Population | 60.0 |
PFS was defined as the time interval between the date of the start of treatment and the date of first documentation of PD or death from any cause, whichever occurred first. Response was based on RECIST v1.0. For TLs, PD was at least a 20 % increase in the sum of LD of TLs, taking as reference the smallest sum LD recorded since the treatment started or the appearance of one or more lesions. For NTLs, PD was the appearance of one or more new lesions and/or unequivocal progression of existing NTLs. Median PFS time was calculated using Kaplan-Meier estimates. Data for participants without PD or death was censored at the time of the last response assessment.
| months | Overall MBC Participants |
|---|---|
| PFS - MBC Population | 13.8 (1.6 to 33.5) |
BOR was defined as CR or PR recorded from baseline until disease progression/recurrence according to RECIST v1.0 criteria. For TLs, CR was defined as the disappearance of all TLs, and PR was defined as at least a 30% decrease in the sum of LDs of the TLs, taking as a reference the baseline (BL) sum of LDs. For NTLs, CR was defined as the disappearance of all NTLs and normalization of tumor marker levels. Percentage of participants with BOR rate was calculated as the (number of participants with CR or PR) divided by (total number of participants), and then multiplied by 100. The 95% confidence interval (Cl) was determined using the Pearson-Clopper method.
| percentage of participants | Overall MBC Participants |
|---|---|
| Percentage of Participants With a Best Overall Response (BOR) of Complete Response (CR) or Partial Response (PR) - MBC Population | 80.0 (59.3 to 93.2) |
Treatment failure was defined as the discontinuation of treatment for any reason, including the following qualifying events: PD, death from any cause, withdrawal from study treatment, or initiation of nonprotocol anti-cancer therapy. Percentage of participants with treatment failure was calculated as the (number of participants with treatment failure) divided by (total number of participants), and then multiplied by 100.
| percentage of participants | Overall MBC Participants |
|---|---|
| Percentage of Participants With Treatment Failure - MBC Population | 64.0 |
TTF was defined as the time interval between the date of start of treatment and the date of PD, death from any cause, withdrawal from study treatment, or initiation of non-protocol anti-cancer therapy, whichever occurred first. Participants without an event at the time of the analysis were censored at the date of the last follow-up assessment. Median TTF was estimated using the Kaplan-Meier method.
| months | Overall MBC Participants |
|---|---|
| Time to Treatment Failure (TTF) - MBC Population | 13.8 (1.4 to 39.8) |
CBR was defined as percentage of participants experiencing SD of at least 6 months from the start of treatment plus CR or PR according to the RECIST v1.0 criteria. For TLs: CR- disappearance of all TLs. PR- at least 30% decrease in the sum of LDs of the TLs, taking as a reference the BL sum of LDs. PD- at least 20% increase in the sum of LD of TLs, taking as reference the smallest sum LD recorded since the treatment started or the appearance of one or more lesions. SD- neither sufficient shrinkage to qualify for PR nor sufficient increase to qualify for PD. For NTLs: CR- disappearance of all NTLs and normalization of tumor marker levels. SD- persistence of one or more NTLs and/or maintenance of tumor marker level above the normal limits. Percentage of participants= number of participants with CR/PR/SD divided by total number of participants, and then multiplied by 100. 95% CI was determined using the Pearson-Clopper method.
| percentage of participants | Overall MBC Participants |
|---|---|
| Percentage of Participants With CR or PR or Stable Disease (SD) for at Least 6 Months [Clinical Benefit Rate (CBR)] - MBC Population | 92.0 (74.0 to 99.0) |
Duration of response was calculated for participants with CR or PR based on the RECIST v1.0 criteria. Duration of response was defined as the time interval between the date the CR or PR was first recorded and the date on which PD was first noted or date of death, whichever occurred first. Participants with no documented PD after CR or PR were censored at the last date at which they were known to have had the CR or PR, respectively. Median duration of response was estimated using the Kaplan-Meier method.
| months | Overall MBC Participants |
|---|---|
| Duration of Response - MBC Population | 12.4 (3.9 to 32.7) |
The pCR was defined as the absence of invasive neoplastic cells at microscopic examination of the tumor remnants and lymph nodes after surgery following primary systemic therapy.
| percentage of participants | LABC: T-DM1 + Doc (Doublet Regimen) | LABC: T-DM1 + Doc + Pertuzumab (Triplet Regimen) |
|---|---|---|
| Percentage of Participants With Pathological CR (pCR) - LABC Population | 60.0 (43.3 to 75.1) | 60.6 (42.1 to 77.1) |
BOR was defined as CR or PR recorded from baseline until disease progression/recurrence according to RECIST v1.0 criteria. For TLs, CR was defined as the disappearance of all TLs, and PR was defined as at least a 30% decrease in the sum of LDs of the TLs, taking as a reference the baseline (BL) sum of LDs. For NTLs, CR was defined as the disappearance of all NTLs and normalization of tumor marker levels. Percentage of participants with BOR rate was calculated as the (number of participants with CR or PR) divided by (total number of participants), and then multiplied by 100. The 95% Cl was determined using the Pearson-Clopper method.
| percentage of participants | LABC: T-DM1 + Doc (Doublet Regimen) | LABC: T-DM1 + Doc + Pertuzumab (Triplet Regimen) |
|---|---|---|
| Percentage of Participants With a BOR of CR or PR - LABC Population | 70.0 (53.5 to 83.4) | 51.5 (33.5 to 69.2) |
Number of participants with ATA response was reported. Data for this outcome measure was planned to be reported for overall MBC and LABC participants and not by individual treatment arms.
| participants | Overall MBC and LABC Participants |
|---|---|
| Baseline | 3 |
| Post-baseline | 3 |
| micrograms per milliliter (mcg/mL) | MBC: T-DM1 2.4 mg/kg | MBC: T-DM1 3.6 mg/kg | LABC: T-DM1 3.6 mg/kg |
|---|---|---|---|
| Cycle 1 | 78.6 ± 16.6 | 76.2 ± 36.4 | 85.7 ± 15.3 |
| Cycle 2 | 78.7 ± 16.7 | 93.7 ± 27.6 | 80.2 ± 18.4 |
| days | MBC: T-DM1 2.4 mg/kg | MBC: T-DM1 3.6 mg/kg | LABC: T-DM1 3.6 mg/kg |
|---|---|---|---|
| Cycle 1 | 2.79 ± 0.637 | 3.45 ± 0.779 | 3.46 ± 0.558 |
| Cycle 2 | 3.14 ± 0.574 | 3.85 ± 0.568 | 3.62 ± 0.516 |
| day*mcg/mL | MBC: T-DM1 2.4 mg/kg | MBC: T-DM1 3.6 mg/kg | LABC: T-DM1 3.6 mg/kg |
|---|---|---|---|
| Cycle 1 | 396 ± 124 | 447 ± 144 | 442 ± 90.7 |
| Cycle 2 | 471 ± 94.5 | 556 ± 223 | 488 ± 123 |
| milliliters/day/kilogram (mL/day/kg) | MBC: T-DM1 2.4 mg/kg | MBC: T-DM1 3.6 mg/kg | LABC: T-DM1 3.6 mg/kg |
|---|---|---|---|
| Cycle 1 | 8.94 ± 12 | 8.87 ± 2.96 | 8.48 ± 1.86 |
| Cycle 2 | 5.21 ± 1.27 | 7.16 ± 2.95 | 7.68 ± 2.73 |
| mL/kg | MBC: T-DM1 2.4 mg/kg | MBC: T-DM1 3.6 mg/kg | LABC: T-DM1 3.6 mg/kg |
|---|---|---|---|
| Cycle 1 | 22.1 ± 6.74 | 33.2 ± 9.13 | 33.2 ± 8.36 |
| Cycle 2 | 17.7 ± 4.73 | 31.4 ± 16.9 | 28.8 ± 9.32 |
| mcg/mL | MBC: T-DM1 2.4 mg/kg | MBC: T-DM1 3.6 mg/kg | LABC: T-DM1 3.6 mg/kg |
|---|---|---|---|
| Cycle 1 | 88.7 ± 22.6 | 89.2 ± 47.4 | 120 ± 46.6 |
| Cycle 2 | 85.8 ± 17.5 | 97.7 ± 29.4 | 113 ± 43.8 |
| days | MBC: T-DM1 2.4 mg/kg | MBC: T-DM1 3.6 mg/kg | LABC: T-DM1 3.6 mg/kg |
|---|---|---|---|
| Cycle 1 | 6.44 ± 2.6 | 6.38 ± 1.41 | 8.12 ± 4.2 |
| Cycle 2 | 6.67 ± 1.92 | 7.83 ± 1.68 | 9.91 ± 5.01 |
| day*mcg/mL | MBC: T-DM1 2.4 mg/kg | MBC: T-DM1 3.6 mg/kg | LABC: T-DM1 3.6 mg/kg |
|---|---|---|---|
| Cycle 1 | 785 ± 429 | 707 ± 201 | 1210 ± 856 |
| Cycle 2 | 809 ± 308 | 1040 ± 359 | 1570 ± 1180 |
| mL/day/kg | MBC: T-DM1 2.4 mg/kg | MBC: T-DM1 3.6 mg/kg | LABC: T-DM1 3.6 mg/kg |
|---|---|---|---|
| Cycle 1 | 6.78 ± 13.3 | 5.45 ± 1.46 | 4.22 ± 2.13 |
| Cycle 2 | 3.32 ± 1.53 | 3.71 ± 1.23 | 3.38 ± 2.11 |
| mL/kg | MBC: T-DM1 2.4 mg/kg | MBC: T-DM1 3.6 mg/kg | LABC: T-DM1 3.6 mg/kg |
|---|---|---|---|
| Cycle 1 | 27 ± 7.16 | 41.3 ± 9.24 | 36.5 ± 12.7 |
| Cycle 2 | 24.6 ± 5.05 | 36.4 ± 11.3 | 35.2 ± 12 |
DM1 is the metabolite of trastuzumab emtansine.
| nanograms per milliliter (ng/mL) | MBC: T-DM1 2.4 mg/kg | MBC: T-DM1 3.6 mg/kg | LABC: T-DM1 3.6 mg/kg |
|---|---|---|---|
| Cycle 1 | 3.55 ± 1.6 | 3.42 ± 0.944 | 4.51 ± 1.38 |
| Cycle 2 | 3.34 ± 0.815 | 3.9 ± 1.19 | 4.65 ± 1.57 |
| days | MBC: T-DM1 2.4 mg/kg | MBC: T-DM1 3.6 mg/kg | LABC: T-DM1 3.6 mg/kg |
|---|---|---|---|
| Cycle 1 | 1.12 ± 0.702 | 1.2 ± 0.985 | 1.87 ± 1.63 |
| Cycle 2 | 3.75 ± 0.912 | 2.91 | 3.32 ± 0.7 |
| day*ng/mL | MBC: T-DM1 2.4 mg/kg | MBC: T-DM1 3.6 mg/kg | LABC: T-DM1 3.6 mg/kg |
|---|---|---|---|
| Cycle 1 | 5.72 ± 5.16 | 5.01 ± 2.54 | 9.38 ± 9.33 |
| Cycle 2 | 17.8 ± 4.6 | 20 | 18.5 ± 4.28 |
Docetaxel infusion duration = 1 hr (as per summary of product characteristics \[SmPC\])
| ng/mL | MBC: Docetaxel 75 mg/m^2 | MBC: Docetaxel 60 mg/m^2 | LABC: Docetaxel 60 mg/m^2 | LABC: Docetaxel 75 mg/m^2 | LABC: Docetaxel 100 mg/m^2 |
|---|---|---|---|---|---|
| Cycle 1 | 500 ± 216 | 1300 ± 829 | 1470 ± 551 | 1710 ± 426 | 2950 ± 1540 |
| Cycle 2 | 791 ± 637 | 1320 ± 826 | 1590 ± 441 | 1960 ± 552 | 2790 ± 979 |
Docetaxel infusion duration = 1 hr (as per SmPC)
| hours (hr) | MBC: Docetaxel 75 mg/m^2 | MBC: Docetaxel 60 mg/m^2 | LABC: Docetaxel 60 mg/m^2 | LABC: Docetaxel 75 mg/m^2 | LABC: Docetaxel 100 mg/m^2 |
|---|---|---|---|---|---|
| Cycle 1 | 6.83 ± 4.22 | 5.17 ± 4.02 | 4.25 ± 5.61 | 8.29 ± 5.75 | 8.76 ± 3.82 |
| Cycle 2 | 7.7 ± 4.15 | 7.88 ± 6.18 | 5.9 ± 3.83 | 6.69 ± 5.55 | 7.24 ± 3.58 |
Docetaxel infusion duration = 1 hr (as per SmPC)
| hr*ng/mL | MBC: Docetaxel 75 mg/m^2 | MBC: Docetaxel 60 mg/m^2 | LABC: Docetaxel 60 mg/m^2 | LABC: Docetaxel 75 mg/m^2 | LABC: Docetaxel 100 mg/m^2 |
|---|---|---|---|---|---|
| Cycle 1 | 1050 ± 475 | 1560 ± 874 | 1540 ± 421 | 2140 ± 669 | 4020 ± 2120 |
| Cycle 2 | 1700 ± 1190 | 1710 ± 875 | 3260 ± 5100 | 2420 ± 887 | 3840 ± 1930 |
Docetaxel infusion duration = 1 hr (as per SmPC)
| liters/hour/square meter (L/hr/m^2) | MBC: Docetaxel 75 mg/m^2 | MBC: Docetaxel 60 mg/m^2 | LABC: Docetaxel 60 mg/m^2 | LABC: Docetaxel 75 mg/m^2 | LABC: Docetaxel 100 mg/m^2 |
|---|---|---|---|---|---|
| Cycle 1 | 82.2 ± 32.6 | 58.3 ± 40.9 | 42.8 ± 16.4 | 39.5 ± 16.8 | 30.5 ± 14.5 |
| Cycle 2 | 59 ± 29.9 | 51.2 ± 38.5 | 32.6 ± 13.1 | 33.6 ± 11.9 | 27.9 ± 9.13 |
Docetaxel infusion duration = 1 hr (as per SmPC)
| liters per square meter (L/m^2) | MBC: Docetaxel 75 mg/m^2 | MBC: Docetaxel 60 mg/m^2 | LABC: Docetaxel 60 mg/m^2 | LABC: Docetaxel 75 mg/m^2 | LABC: Docetaxel 100 mg/m^2 |
|---|---|---|---|---|---|
| Cycle 1 | 530 ± 398 | 203 ± 275 | 75 ± 113 | 126 ± 86.7 | 116 ± 73.3 |
| Cycle 2 | 380 ± 257 | 253 ± 234 | 93.2 ± 64.7 | 79 ± 53.6 | 84.8 ± 39.1 |
Collected over Baseline up to 28 days after last dose for MBC participants and for LABC participants who could not undergo surgery, and up to 6 weeks post-surgery for LABC participants who underwent surgery (maximum up to approximately 3 years). Non-serious events are listed at a 5% frequency threshold.
| Group | Deaths | Serious | Other |
|---|---|---|---|
| MBC: T-DM1 2.4 mg/kg + Doc 75 mg/m^2 (Over 2 Days) | — | 2/6 (33.3%) | 6/6 (100%) |
| MBC: T-DM1 2.4 mg/kg + Doc 60 mg/m^2 (Over 2 Days) | — | 2/6 (33.3%) | 6/6 (100%) |
| MBC: T-DM1 2.4 mg/kg + Doc 60 mg/m^2 (Same Day) | — | 2/3 (66.7%) | 3/3 (100%) |
| MBC: T-DM1 3.6 mg/kg + Doc 60 mg/m^2 (Same Day) | — | 4/10 (40%) | 10/10 (100%) |
| LABC: T-DM1 + Doc (Doublet Regimen) | — | 9/40 (22.5%) | 40/40 (100%) |
| LABC: T-DM1 + Doc + Pertuzumab (Triplet Regimen) | — | 9/33 (27.3%) | 33/33 (100%) |
| Event | MBC: T-DM1 2.4 mg/kg + Doc 75 mg/m^2 (Over 2 Days) | MBC: T-DM1 2.4 mg/kg + Doc 60 mg/m^2 (Over 2 Days) | MBC: T-DM1 2.4 mg/kg + Doc 60 mg/m^2 (Same Day) | MBC: T-DM1 3.6 mg/kg + Doc 60 mg/m^2 (Same Day) | LABC: T-DM1 + Doc (Doublet Regimen) | LABC: T-DM1 + Doc + Pertuzumab (Triplet Regimen) |
|---|---|---|---|---|---|---|
| AnxietyPsychiatric disorders | 0/6 | 0/6 | 1/3 | 0/10 | 0/40 | 0/33 |
| Febrile neutropeniaBlood and lymphatic system disorders | 1/6 | 1/6 | 1/3 | 0/10 | 1/40 | 1/33 |
| Thrombosis in deviceGeneral disorders | 1/6 | 1/6 | 0/3 | 0/10 | 0/40 | 0/33 |
| NeutropeniaBlood and lymphatic system disorders | 0/6 | 1/6 | 0/3 | 0/10 | 1/40 | 2/33 |
| ThrombocytopeniaBlood and lymphatic system disorders | 1/6 | 0/6 | 0/3 | 0/10 | 1/40 | 1/33 |
| Hepatocellular injuryHepatobiliary disorders | 1/6 | 0/6 | 0/3 | 0/10 | 0/40 | 1/33 |
| CholecystitisHepatobiliary disorders | 1/6 | 0/6 | 0/3 | 0/10 | 0/40 | 0/33 |
| Viral infectionInfections and infestations | 0/6 | 1/6 | 0/3 | 0/10 | 1/40 | 1/33 |
| HaematomaVascular disorders | 0/6 | 0/6 | 0/3 | 1/10 | 0/40 | 0/33 |
| Tibia fractureInjury, poisoning and procedural complications | 0/6 | 0/6 | 0/3 | 1/10 | 0/40 | 0/33 |
| Event | MBC: T-DM1 2.4 mg/kg + Doc 75 mg/m^2 (Over 2 Days) | MBC: T-DM1 2.4 mg/kg + Doc 60 mg/m^2 (Over 2 Days) | MBC: T-DM1 2.4 mg/kg + Doc 60 mg/m^2 (Same Day) | MBC: T-DM1 3.6 mg/kg + Doc 60 mg/m^2 (Same Day) | LABC: T-DM1 + Doc (Doublet Regimen) | LABC: T-DM1 + Doc + Pertuzumab (Triplet Regimen) |
|---|---|---|---|---|---|---|
| AstheniaGeneral disorders | 6/6 | 5/6 | 1/3 | 6/10 | 25/40 | 20/33 |
| NeutropeniaBlood and lymphatic system disorders | 6/6 | 5/6 | 1/3 | 7/10 | 11/40 | 12/33 |
| ConstipationGastrointestinal disorders | 1/6 | 1/6 | 3/3 | 3/10 | 19/40 | 11/33 |
| PyrexiaGeneral disorders | 1/6 | 5/6 | 0/3 | 2/10 | 8/40 | 10/33 |
| EpistaxisRespiratory, thoracic and mediastinal disorders | 2/6 | 5/6 | 1/3 | 6/10 | 21/40 | 19/33 |
| LeukopeniaBlood and lymphatic system disorders | 5/6 | 3/6 | 1/3 | 4/10 | 3/40 | 3/33 |
| LymphopeniaBlood and lymphatic system disorders | 5/6 | 1/6 | 0/3 | 3/10 | 3/40 | 4/33 |
| NauseaGastrointestinal disorders | 1/6 | 5/6 | 1/3 | 4/10 | 16/40 | 16/33 |
| ThrombocytopeniaBlood and lymphatic system disorders | 4/6 | 4/6 | 0/3 | 8/10 | 9/40 | 7/33 |
| DyspnoeaRespiratory, thoracic and mediastinal disorders | 1/6 | 2/6 | 2/3 | 4/10 | 4/40 | 1/33 |
All participants who received at least one dose of study medication were included.
| Age, Continuous(years) | MBC: T-DM1 2.4 mg/kg + Doc 75 mg/m^2 (Over 2 Days) | MBC: T-DM1 2.4 mg/kg + Doc 60 mg/m^2 (Over 2 Days) | MBC: T-DM1 2.4 mg/kg + Doc 60 mg/m^2 (Same Day) | MBC: T-DM1 3.6 mg/kg + Doc 60 mg/m^2 (Same Day) | LABC: T-DM1 + Doc (Doublet Regimen) | LABC: T-DM1 + Doc + Pertuzumab (Triplet Regimen) | Total |
|---|---|---|---|---|---|---|---|
| Mean | 43 ± 7.16 | 50.7 ± 4.84 | 57 ± 12.12 | 48 ± 9.39 | 48.6 ± 9.73 | 54.2 ± 11.43 | 50.4 ± 10.39 |
| Sex: Female, Male(Participants) | MBC: T-DM1 2.4 mg/kg + Doc 75 mg/m^2 (Over 2 Days) | MBC: T-DM1 2.4 mg/kg + Doc 60 mg/m^2 (Over 2 Days) | MBC: T-DM1 2.4 mg/kg + Doc 60 mg/m^2 (Same Day) | MBC: T-DM1 3.6 mg/kg + Doc 60 mg/m^2 (Same Day) | LABC: T-DM1 + Doc (Doublet Regimen) | LABC: T-DM1 + Doc + Pertuzumab (Triplet Regimen) | Total |
|---|---|---|---|---|---|---|---|
| Female | 6 | 6 | 3 | 10 | 40 | 33 | 98 |
| Male | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
Ran from Jul 2009 to primary completion in Oct 2013, 51 months.
Results were first posted in Apr 2017, 3 years 6 months after primary completion.
Of 161 industry-sponsored phase 1/2 interventional studies under Breast Neoplasms, half reached primary completion within 59 months of starting (the median), counting those still running; a quarter within 44 and three quarters within 75. This study's 51 months is below that.
Counting every sponsor, half of 327 studies reached it within 61 months; a quarter within 45 and three quarters within 88.
How these figures are worked out, and which studies are left out of them.
This study is completed, as verified in Feb 2017. You cannot join it, but the record below documents what was studied.
Get an email when the registry record changes — status, dates, results — or when someone posts here.
Sign in to followQuestions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.
Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.
Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.
Studies of the drugs tested here: Docetaxel · Ado-Trastuzumab Emtansine